Orencia Alternatives Compared
| Orencia (abatacept) | Xeljanz (tofacitinib) | Methotrexate |
|
|---|
| Orencia (abatacept) | Xeljanz (tofacitinib) | Methotrexate |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Orencia is a selective immunosuppressant that may be used to treat inflammatory conditions such as rheumatoid arthritis or psoriatic arthritis. It is administered by intravenous infusion every 4... View more |
Prescription only
Xeljanz is a Janus kinase (JAK) inhibitor that may be used to reduce inflammation associated with several conditions such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, or... View more |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Related suggestions Rheumatoid Arthritis
Polyarticular Juvenile Idiopathic Arthritis
Popular comparisons
|
|||||||||||||||||||||||
| More about Orencia (abatacept) | More about Xeljanz (tofacitinib) | More about Methotrexate | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Orencia has an average rating of 6.0 out of 10 from a total of 71 ratings on Drugs.com. 46% of reviewers reported a positive effect, while 34% reported a negative effect. |
Xeljanz has an average rating of 5.7 out of 10 from a total of 145 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 40% reported a negative effect. |
Methotrexate has an average rating of 6.5 out of 10 from a total of 335 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Orencia side effects |
View all Xeljanz side effects |
View all Methotrexate side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Orencia prices |
View all Xeljanz prices |
View all Methotrexate prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other tofacitinib brands include: Xeljanz Oral Solution, Xeljanz XR | Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
600 hours |
3 hours |
15 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 165 drugs are known to interact with Orencia:
|
A total of 655 drugs are known to interact with Xeljanz:
|
A total of 716 drugs are known to interact with Methotrexate:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 23, 2005 |
November 06, 2012 |
December 07, 1953 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.